JMP Securities Increases Axon Enterprise (NASDAQ:AXON) Price Target to $375.00

Axon Enterprise (NASDAQ:AXON) had its price target raised by JMP Securities from $320.00 to $375.00 in a research report released on Wednesday, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on AXON. William Blair reiterated an outperform rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Barclays upped their price objective on Axon Enterprise from $296.00 to $308.00 and gave the stock an overweight rating in a research note on Thursday, February 29th. The Goldman Sachs Group upped their price objective on Axon Enterprise from $297.00 to $339.00 and gave the stock a buy rating in a research note on Wednesday, February 28th. StockNews.com lowered Axon Enterprise from a buy rating to a hold rating in a research note on Thursday, March 14th. Finally, TheStreet lowered Axon Enterprise from a b rating to a c+ rating in a research note on Tuesday, February 27th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Axon Enterprise has an average rating of Moderate Buy and a consensus price target of $323.09.

Axon Enterprise Price Performance

Shares of AXON opened at $318.55 on Wednesday. The firm has a market cap of $24.04 billion, a PE ratio of 138.50 and a beta of 0.91. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The firm has a fifty day simple moving average of $308.83 and a two-hundred day simple moving average of $265.28. Axon Enterprise has a 1-year low of $175.37 and a 1-year high of $329.87.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.29. The business had revenue of $432.14 million during the quarter, compared to analyst estimates of $418.97 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. On average, equities analysts anticipate that Axon Enterprise will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AXON. Westfield Capital Management Co. LP boosted its holdings in shares of Axon Enterprise by 184.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock valued at $138,535,000 after purchasing an additional 451,350 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of Axon Enterprise by 18.4% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 104,587 shares of the biotechnology company’s stock valued at $27,019,000 after purchasing an additional 16,230 shares during the last quarter. BKM Wealth Management LLC bought a new position in shares of Axon Enterprise during the 4th quarter valued at about $32,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Axon Enterprise by 0.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 147,345 shares of the biotechnology company’s stock valued at $29,320,000 after purchasing an additional 495 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of Axon Enterprise during the 4th quarter valued at about $39,907,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.